Loading...
XNAS
FBRX
Market cap285mUSD
Jul 09, Last price  
36.70USD
1D
78.33%
1Q
4.59%
IPO
-99.25%
Name

Forte Biosciences Inc

Chart & Performance

D1W1MN
XNAS:FBRX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
246.57%
Rev. gr., 5y
-3.65%
Revenues
0k
51,00049,00041,00018,036,0000000000
Net income
-69m
L+95.54%
-23,056,000-33,478,000-38,929,000-48,955,000-4,069,000-46,487,000-21,708,000-13,862,000-31,476,000-35,478,000-69,375,000
CFO
-51m
L+65.50%
-21,042,000-29,539,000-31,133,000-34,469,000-2,771,000-18,423,000-16,677,000-8,185,000-28,706,000-30,745,000-50,882,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
URL
https://www.fortebiorx.com/
IPO date
Apr 13, 2017
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT